title: A 17-year experience of abobotulinumtoxina in cervical dystonia.
abstract: OBJECTIVE
  To investigate the long-term efficacy and safety of a botulinum toxin type A (BoNT-A) for the treatment of cervical dystonia (CD).
  
  
  METHODS
  We conducted a retrospective chart review of patients with CD treated with abobotulinumtoxinA (Dysport™ 100-800 units [U] for injection) between 1993 and 2009 at the University Hospital "La Paz" (LPUH). Affected muscles were selected using electromyography (EMG).
  
  
  RESULTS
  Thirty-seven patients were included in the study; most were female (62%) and had idiopathic CD (60%). Almost half (46%) of patients were diagnosed with the condition more than 10 years ago. The most common clinical presentations of CD were rotation (46%) and laterocollis (43%). On average, patients were treated with Dysport for 7 years (range: 1-17 years) and received 487 (range: 320 to 650) U over 15.9 (range: 1 to 40) injection cycles. Most (97%) patients maintained a response from treatment initiation to end of evaluation period. Overall, 70% of patients were taking concomitant oral medication. Dysport was generally well tolerated. Dysphagia was reported by 18.9% of patients, but this did not lead to discontinuation of Dysport treatment.
  
  
  CONCLUSIONS
  These data confirm the long-term efficacy and safety of Dysport in CD over a period of up to 17 years.
authors.affiliation: Neurology Department, Movement Disorder Unit, [corrected] La Paz University Hospital, Paseo Castellana 261, Madrid, Spain. Fvivancos@hotmail.es
authors.forename: Francisco
authors.initials: F
authors.lastname: Vivancos-Matellano
authors.forename: Isabel
authors.initials: I
authors.lastname: Ybot-Gorrin
authors.forename: Exuperio
authors.initials: E
authors.lastname: Diez-Tejedor
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002648:Child; D004576:Electromyography; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014103:Torticollis / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA